BAT5906 vs Ranibizumab (Ximluci)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

BAT5906

Developed by Bio-Thera Solutions

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
Partial signal

NCT05439629 · Phase 3 · completed

The study randomized 488 participants to BAT5906 or active treatment with Lucentis and masked participants, care providers, and investigators. Its primary outcomes were clinical measures of visual acuity, but the registry does not report whether the comparison was favorable or statistically significant, so the evidence remains limited pending results.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Ranibizumab (Ximluci)

Marketed by STADA Arzneimittel and partners

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

BAT5906: no structured comparison results are available for Age-Related Macular Degeneration.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ranibizumab (Ximluci)

BCVA Change Letters 4.57 vs 6.37 Lucentis Letters @ 8wk
absolute change · Letters
NCT03805100 · Phase 3
CNV Leakage Area -4.09 vs -3.71 Lucentis mm2 @ 52wk
absolute change · mm2
NCT03805100 · Phase 3
CNV Area Change Mm2 -1.62 vs -1.11 Lucentis mm2 @ 52wk
absolute change · mm2
NCT03805100 · Phase 3
CFT Change Microns -117.44 vs -115.14 Lucentis um @ 52wk
absolute change · um
NCT03805100 · Phase 3
Available safety results

Ranibizumab (Ximluci)

Dropout rate
16.1%
NCT03805100 · Phase 3
Discontinued due to AEs
—
NCT03805100 · Phase 3
Serious AEs
11.3%
NCT03805100 · Phase 3
Most frequent reported AEs
conjunctival haemorrhage 5.1%
hypertension 3.4%
NCT03805100 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT5906's landscape · Ranibizumab (Ximluci)'s landscape